Moreover, despite the fact that around two-thirds of SRRM4-regulated exons are not included outside of the brain, we observe that a majority of these exons that change in cancer are decreased in tumors, implying that the one-third of SRRM4 exons that are nonzero outside of the brain are sufficient to promote this antiproliferative effect. Here, SRRM4 is linked to cancer.